<DOC>
	<DOCNO>NCT01478503</DOCNO>
	<brief_summary>The study aim compare age gender difference increase dos mirabegron give healthy young elderly male healthy young elderly female .</brief_summary>
	<brief_title>To Evaluate Blood Urine Concentration Safety Tolerability Increasing Repeated Doses Mirabegron ( YM178 ) OCAS Healthy Young Elderly Males Healthy Young Elderly Females</brief_title>
	<detailed_description>Each subject receive single dose mirabegron OCAS-M placebo Day 2 , follow multiple dosing ( qd ) 10 day ( Day 5-14 ) . Young subject divide 4 group elderly subject 2 group . Dosage different among group .</detailed_description>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Healthy young subject age 1855 year ( inclusive ) Healthy elderly subject age 6580 year ( inclusive ) Body weight 60.0 100.0 kg ( male ) 50.0 90.0 kg ( female ) , Body Mass Index 18.0 30.0 kg/m2 Known suspected hypersensitivity βadrenergic receptor agonists component formulation use Any liver function test ( i.e . ALT , AST bilirubin ) upper limit normal repeated measure Any clinically significant history disease disorder gastrointestinal , cardiovascular , respiratory , renal , hepatic , neurological , dermatological , psychiatric metabolic judge medical investigator . Any clinically significant abnormality follow investigator 's review prestudy physical examination , electrocardiogram ( ECG ) clinical laboratory test Subjects take β blocker β agonist Use prescribe Overthecounter ( OTC ) drug ( include vitamin , natural herbal remedy , e.g . St. John 's wort ) 2 week prior admission Clinical Unit , except occasional use paracetamol ( 3 g/day ) Regular use inducer liver metabolism ( e.g . barbiturate , rifampicin ) 3 month prior admission Clinical Unit Donation blood blood product within 3 month prior admission Clinical Unit Any use drug abuse , smoke 10 cigarette ( equivalent ) 21 unit alcohol per week within 3 month prior study Participation clinical study within 3 month participation 3 clinical study within 12 month , prior expect date enrolment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Dose-Escalation</keyword>
</DOC>